1. Inhibition of histone deacetylation rescues phenotype in a mouse model of Birk-Barel intellectual disability syndrome.
- Author
-
Cooper A, Butto T, Hammer N, Jagannath S, Fend-Guella DL, Akhtar J, Radyushkin K, Lesage F, Winter J, Strand S, Roeper J, Zechner U, and Schweiger S
- Subjects
- Animals, Behavior, Animal, Benzamides, Brain metabolism, Craniofacial Abnormalities drug therapy, Disease Models, Animal, Female, Gene Knockdown Techniques, Genomic Imprinting, Histone Deacetylase Inhibitors pharmacology, Humans, Intellectual Disability drug therapy, Locus Coeruleus metabolism, Male, Mice, Mice, Inbred C57BL, Mice, Knockout, Muscle Hypotonia drug therapy, Mutation, Phenotype, Phenylenediamines pharmacology, Potassium Channels deficiency, Potassium Channels metabolism, Up-Regulation drug effects, Craniofacial Abnormalities genetics, Craniofacial Abnormalities metabolism, Histones metabolism, Intellectual Disability genetics, Intellectual Disability metabolism, Muscle Hypotonia genetics, Muscle Hypotonia metabolism, Potassium Channels genetics
- Abstract
Mutations in the actively expressed, maternal allele of the imprinted KCNK9 gene cause Birk-Barel intellectual disability syndrome (BBIDS). Using a BBIDS mouse model, we identify here a partial rescue of the BBIDS-like behavioral and neuronal phenotypes mediated via residual expression from the paternal Kcnk9 (Kcnk9
pat ) allele. We further demonstrate that the second-generation HDAC inhibitor CI-994 induces enhanced expression from the paternally silenced Kcnk9 allele and leads to a full rescue of the behavioral phenotype suggesting CI-994 as a promising molecule for BBIDS therapy. Thus, these findings suggest a potential approach to improve cognitive dysfunction in a mouse model of an imprinting disorder.- Published
- 2020
- Full Text
- View/download PDF